Valor202020212022202320242025TTMGastos comerciales, generales y administrativos191.66 M283.94 M310.68 M313.94 M344.39 M365.34 M365.34 MInvestigación y desarrollo8.23 M21.87 M30.33 M27.31 M31.16 M37.08 M37.08 MBeneficio operativo-13.99 M-118.75 M-157.62 M-107.74 M-92.11 M-115.88 M-115.88 MTotal de ingresos no operativos11.86 M-499 K1.83 M644 K18.05 M9.37 M9.37 MGastos por intereses, netos de intereses capitalizados7.02 M5.08 M1.51 M6.91 M6.62 M3.75 M3.75 MIngresos no operativos, una vez deducidos los gastos por intereses-7.02 M-5.08 M542 K-6.91 M11.81 M5.32 M5.32 MIngresos/gastos extraordinarios11.86 M-499 K-213 K644 K-379 K296 K296 KBeneficio antes de impuestos-14.06 M-15.07 M-159.34 M-97.1 M-80.67 M-110.27 M-110.27 MParticipación en los beneficios———————Impuestos-18.23 M-6.73 M-15.09 M-9.13 M-1.95 M-2.24 M-2.24 MParticipación minoritaria———————Otros ingresos/gastos después de impuestos-1.46 M-2.55 M-1.71 M————Beneficio neto antes de actividades interrumpidas4.17 M-8.35 M-144.25 M-87.97 M-78.73 M-108.03 M-108.03 MOperaciones suspendidas———————Beneficio neto4.17 M-8.35 M-144.25 M-87.97 M-78.73 M-108.03 M-108.03 MAjuste por dilución0——————Dividendos de las acciones preferentes0——————Beneficio neto diluido atribuible a los accionistas4.17 M-8.35 M-144.25 M-87.97 M-78.73 M-108.03 M-108.03 MBeneficio básico por acción0.04-0.07-1.16-0.7-0.62-0.84-0.84Beneficio por acción diluido0.04-0.07-1.16-0.7-0.62-0.84-0.84Número medio de acciones ordinarias108.58 M119.96 M124.22 M125.5 M126.66 M128.1 M511.84 MAcciones diluidas111.79 M119.96 M124.22 M125.5 M126.66 M128.1 M511.84 MEBITDA26.25 M-62.66 M-85.35 M-32.28 M-16.64 M-46.06 M-21.94 MEBIT-13.99 M-118.75 M-157.62 M-107.74 M-92.11 M-115.88 M-115.88 MCosto de los ingresos258.56 M297.27 M321.83 M347.04 M370.47 M413.04 M413.04 MOtros costes de producción—————400 K400 KAmortización y depreciación (flujo de caja)40.24 M56.09 M72.27 M75.46 M75.46 M69.82 M93.94 M
NeoGenomics Inc
NeoGenomics Laboratories, Inc., also known as NeoGenomics or Neo, is an American CLIA-certified clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing. The company's testing services include cytogenetics, fluorescence in situ hybridization, flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics.
Headquartered in Fort Myers, FL, NeoGenomics maintains a network of testing facilities across the US, with laboratories in Florida, California, Tennessee, and Texas.